Functions · R&D

R&D / Discovery

Decide where to point a programme before you commit budget: how crowded an indication is, what has already failed, and which mechanisms the field is converging on.

16ranked use cases
#1highest overall rank: Indication prioritization
1 clickfrom recipe to a board with the right charts
Lead chart, on real data

What this team sees first.

A bullseye reads crowding at a glance: the closer to the centre, the closer to market. The GI landscape is dense in ulcerative colitis and Crohn's, and thin in celiac disease.

Every use case below opens with its signature chart and a recommended set of supporting views, chosen from 91 chart types.

Built for: Head of Discovery, Competitive Intelligence Lead, R&D Portfolio Strategist, Discovery Biologist, Clinical Development Lead.

Bullseye · Active industry GI trialsReal data
  • Ulcerative colitis8628 in P3
  • Crohn's disease5327 in P3
  • UC and Crohn's188 in P3
  • Eosinophilic GI73 in P3
  • Celiac disease50 in P3

ClinicalTrials.gov, pulled 11 Sep 2026. Interventional, industry lead sponsor, Phase 1–3, active (n = 169). Multi-phase trials placed at the highest phase. Dot positions within a band are for display.

The 16 questions

Ranked by stakes, centrality, reach, frequency and data fit.

Each use case ships with an executive brief, a detailed dossier and a recipe that builds the board in one click.

  • RD-01
    #1

    Indication prioritization

    Assess how crowded or open a therapeutic area is before committing to a new program.

    For: Head of Discovery / R&D Portfolio Strategist
    BullseyeTimelineQuadrant map
  • RD-02
    #2

    Competitive pipeline mapping

    Build a full picture of a competitor's active, completed and terminated trials across all indications.

    For: Competitive Intelligence Lead
    BullseyeStacked bar chartTimeline
  • RD-11N
    #3

    Indication attractiveness index (burden × crowding × access × IP)

    Composite score per indication fusing disease burden, trial crowding, approved-treatment gap, HTA receptivity and IP headroom.

    For: R&D Portfolio Strategist / Head of Discovery
    BullseyeBubble chartStacked area / share-over-time
  • RD-12N
    #11

    Target tractability & validation scoring

    Score a target by genetic association, existing bioactivity/chemistry and the volume and stage of trials pursuing it.

    For: Discovery Biologist / Target Biology Lead
    BullseyeStacked bar chartTimeline
  • RD-03
    #18

    Study design benchmarking

    See the most common trial designs used in your indication before drafting your own protocol.

    For: Clinical Development Lead
    Feature-by-feature alignment chartStacked area / share-over-timeBubble chart
  • RD-04
    #29

    Biomarker & eligibility intelligence

    Learn what patient-stratification criteria competitors use to inform your own inclusion/exclusion design.

    For: Clinical Scientist / Translational Lead
    Slope chartHeatmap / matrixStacked bar chart
  • RD-05
    #30

    Failed trial analysis

    Understand what approaches have already failed and why, to avoid redundant R&D investment.

    For: Discovery / Translational Scientist
    Bar / column chartKPI / metric snapshot panelStacked area / share-over-time
  • RD-06
    #31

    Trend analysis over time

    Spot acceleration or decline of trial activity in an indication to catch emerging fields early.

    For: R&D Strategy / Foresight Analyst
    TimelineBullseyeFan chart
  • RD-13N
    #32

    Competitive mechanism-of-action (MOA) crowding

    Quantify how many programs target the same mechanism, normalised by MOA rather than drug name.

    For: Competitive Intelligence / Translational Lead
    BullseyeBar / column chartTimeline
  • RD-14N
    #42

    Translational target-to-clinic map

    Trace the full chain from target to chemistry to trials to approvals for a mechanism.

    For: Translational / R&D Strategy Lead
    BullseyeBar / column chartStacked area / share-over-time
  • RD-15N
    #52

    Freedom-to-operate & patent-landscape scan

    Map the patent estate around a target, modality or candidate to flag freedom-to-operate risk early.

    For: R&D / IP Strategy / BD Diligence Lead
    BullseyeKPI / metric snapshot panelStacked area / share-over-time
  • RD-16N
    #62

    Digital endpoint & DHT adoption tracking

    Track adoption of digital health technologies and digital endpoints across trials over time.

    For: Clinical Innovation / Digital Endpoints Lead
    TimelineStacked bar chartLine chart
  • RD-07
    #74

    Target validation

    Gauge scientific consensus on a mechanism or drug class by counting trials investigating it.

    For: Discovery Biologist / Target Biology Lead
    Quadrant mapBullseyeBar / column chart
  • RD-08
    #75

    Academic collaboration identification

    Find academic institutions running trials in your space as potential collaboration or licensing partners.

    For: R&D Alliances / External Innovation Lead
    Force-directed network graphPareto chartBipartite network
  • RD-09
    #85

    Combination therapy scouting

    Understand what drug combinations are being explored in your indication, and by whom.

    For: Translational / Combination Strategy Scientist
    Heatmap / matrixBullseyeFunnel chart
  • RD-10
    #92

    Secondary indication discovery

    Spot off-label or secondary uses of your compound class being explored by others.

    For: Portfolio Strategy / Lifecycle Lead
    Quadrant mapBullseyeTimeline
Try it

Ask the registry a r&d question.

Ask the registryAI-assisted

AI reads your question into filters; every number comes straight from the ClinicalTrials.gov API. Don't enter personal or confidential information.

Bring one r&d question to a pilot.

Eight weeks, one programme, success criteria agreed up front.

Plan a pilot